Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $35.70.

VRDN has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. TD Cowen assumed coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Royal Bank of Canada increased their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $15.26 on Thursday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.24 billion, a PE ratio of -3.54 and a beta of 1.05. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The firm’s 50-day simple moving average is $17.02 and its two-hundred day simple moving average is $19.72.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Research analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Voya Investment Management LLC grew its holdings in shares of Viridian Therapeutics by 5.1% during the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock valued at $410,000 after purchasing an additional 1,038 shares during the last quarter. Tudor Investment Corp ET AL boosted its position in Viridian Therapeutics by 3.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock valued at $735,000 after buying an additional 1,106 shares during the period. R Squared Ltd bought a new stake in Viridian Therapeutics in the 4th quarter worth $26,000. Summit Investment Advisors Inc. increased its position in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after acquiring an additional 1,516 shares during the period. Finally, AlphaQuest LLC raised its stake in shares of Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after acquiring an additional 1,519 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.